Ascendis Pharma A/S Reports First Quarter 2019 Financial Results
– Continued execution of global endocrinology rare disease programs, following validation of TransCon™ platform in phase 3 heiGHt Trial – – R&D Day on June 26 to feature endocrinology and introduction of oncology – – Conference call today at 4:30 p.m. …